Effectiveness Of Bnt162b2 (pfizer-biontech) Mrna Vaccination Against Multisystem Inflammatory Syndrome In Children Among Persons Aged 12-18 Years - United States, July-december 2021
Document Type
Article
Publication Date
1-7-2022
Publication Title
Morbidity and Mortality Weekly Report
First Page
52
Last Page
58
PubMed ID
35025852
Volume
71
Issue
2
Recommended Citation
Zambrano, Laura D.; Newhams, Margaret M.; Olson, Samantha M.; Halasa, Natasha B.; Price, Ashley M.; Boom, Julie A.; Sahni, Leila C.; Kamidani, Satoshi; Tarquinio, Keiko M.; Maddux, Aline B.; Heidemann, Sabrina M.; Bhumbra, Samina S.; Bline, Katherine E.; Nofziger, Ryan A.; Hobbs, Charlotte V.; Bradford, Tamara T.; Cvijanovich, Natalie Z.; Irby, Katherine; MacK, Elizabeth H.; Cullimore, Melissa L.; Pannaraj, Pia S.; Kong, Michele; Walker, Tracie C.; Gertz, Shira J.; Michelson, Kelly N.; Cameron, Melissa A.; Chiotos, Kathleen; and Maamari, Mia, "Effectiveness Of Bnt162b2 (pfizer-biontech) Mrna Vaccination Against Multisystem Inflammatory Syndrome In Children Among Persons Aged 12-18 Years - United States, July-december 2021" (2022). School of Medicine Faculty Publications. 1357.
https://digitalscholar.lsuhsc.edu/som_facpubs/1357
10.15585/MMWR.MM7102E1